Back Relentless Save as PDF
Chapters (209)
  1. Title Page
  2. Copyright Notice
  3. Dedication
  4. PART 1
  5. CHAPTER 1
  6. CHAPTER 2
  7. CHAPTER 3
  8. INTERLUDE 1
  9. CHAPTER 4
  10. INTERLUDE 2
  11. CHAPTER 5
  12. INTERLUDE 3
  13. CHAPTER 6
  14. CHAPTER 7
  15. INTERLUDE 4
  16. CHAPTER 8
  17. CHAPTER 9
  18. CHAPTER 10
  19. CHAPTER 11
  20. CHAPTER 12
  21. CHAPTER 13
  22. INTERLUDE 5
  23. CHAPTER 14
  24. INTERLUDE 6
  25. PART 2
  26. CHAPTER 15
  27. INTERLUDE 7
  28. CHAPTER 16
  29. CHAPTER 17
  30. CHAPTER 18
  31. CHAPTER 19
  32. INTERLUDE 8
  33. CHAPTER 20
  34. CHAPTER 21
  35. CHAPTER 22
  36. CHAPTER 23
  37. CHAPTER 24
  38. CHAPTER 25
  39. CHAPTER 26
  40. CHAPTER 27
  41. CHAPTER 28
  42. CHAPTER 29
  43. CHAPTER 30
  44. CHAPTER 31
  45. CHAPTER 32
  46. INTERLUDE 9
  47. CHAPTER 33
  48. CHAPTER 34
  49. CHAPTER 35
  50. PART 3
  51. CHAPTER 36
  52. CHAPTER 37
  53. CHAPTER 38
  54. CHAPTER 39
  55. CHAPTER 40
  56. CHAPTER 41
  57. CHAPTER 42
  58. CHAPTER 43
  59. CHAPTER 44
  60. CHAPTER 45
  61. CHAPTER 46
  62. INTERLUDE 10
  63. CHAPTER 47
  64. CHAPTER 48
  65. CHAPTER 49
  66. CHAPTER 50
  67. CHAPTER 51
  68. INTERLUDE 11
  69. CHAPTER 52
  70. CHAPTER 53
  71. CHAPTER 54
  72. CHAPTER 55
  73. CHAPTER 56
  74. CHAPTER 57
  75. INTERLUDE 12
  76. CHAPTER 58
  77. CHAPTER 59
  78. CHAPTER 60
  79. CHAPTER 61
  80. CHAPTER 62
  81. CHAPTER 63
  82. CHAPTER 64
  83. CHAPTER 65
  84. CHAPTER 66
  85. CHAPTER 67
  86. CHAPTER 68
  87. CHAPTER 69
  88. CHAPTER 70
  89. CHAPTER 71
  90. PART 4
  91. CHAPTER 72
  92. CHAPTER 73
  93. CHAPTER 74
  94. CHAPTER 75
  95. INTERLUDE 13
  96. CHAPTER 76
  97. CHAPTER 77
  98. CHAPTER 78
  99. CHAPTER 79
  100. CHAPTER 80
  101. CHAPTER 81
  102. INTERLUDE 14
  103. CHAPTER 82
  104. CHAPTER 83
  105. CHAPTER 84
  106. CHAPTER 85
  107. CHAPTER 86
  108. PART 5
  109. CHAPTER 87
  110. CHAPTER 88
  111. CHAPTER 89
  112. CHAPTER 90
  113. CHAPTER 91
  114. CHAPTER 92
  115. CHAPTER 93
  116. CHAPTER 94
  117. CHAPTER 95
  118. CHAPTER 96
  119. CHAPTER 97
  120. CHAPTER 98
  121. CHAPTER 99
  122. CHAPTER 100
  123. CHAPTER 101
  124. CHAPTER 102
  125. CHAPTER 103
  126. CHAPTER 104
  127. CHAPTER 105
  128. CHAPTER 106
  129. CHAPTER 107
  130. CHAPTER 108
  131. CHAPTER 109
  132. CHAPTER 110
  133. CHAPTER 111
  134. CHAPTER 112
  135. CHAPTER 113
  136. CHAPTER 114
  137. CHAPTER 115
  138. CHAPTER 116
  139. PART 6
  140. CHAPTER 117
  141. CHAPTER 118
  142. CHAPTER 119
  143. CHAPTER 120
  144. CHAPTER 121
  145. CHAPTER 122
  146. CHAPTER 123
  147. CHAPTER 124
  148. CHAPTER 125
  149. CHAPTER 126
  150. CHAPTER 127
  151. CHAPTER 128
  152. CHAPTER 129
  153. CHAPTER 130
  154. CHAPTER 131
  155. CHAPTER 132
  156. CHAPTER 133
  157. CHAPTER 134
  158. CHAPTER 135
  159. CHAPTER 136
  160. CHAPTER 137
  161. CHAPTER 138
  162. CHAPTER 139
  163. CHAPTER 140
  164. CHAPTER 141
  165. CHAPTER 142
  166. PART 7
  167. CHAPTER 143
  168. CHAPTER 144
  169. CHAPTER 145
  170. CHAPTER 146
  171. CHAPTER 147
  172. CHAPTER 148
  173. CHAPTER 149
  174. CHAPTER 150
  175. CHAPTER 151
  176. CHAPTER 152
  177. CHAPTER 153
  178. CHAPTER 154
  179. CHAPTER 155
  180. CHAPTER 156
  181. CHAPTER 157
  182. CHAPTER 158
  183. CHAPTER 159
  184. CHAPTER 160
  185. CHAPTER 161
  186. CHAPTER 162
  187. CHAPTER 163
  188. CHAPTER 164
  189. CHAPTER 165
  190. CHAPTER 166
  191. CHAPTER 167
  192. CHAPTER 168
  193. CHAPTER 169
  194. CHAPTER 170
  195. CHAPTER 171
  196. CHAPTER 172
  197. CHAPTER 173
  198. CHAPTER 174
  199. CHAPTER 175
  200. CHAPTER 176
  201. CHAPTER 177
  202. CHAPTER 178
  203. CHAPTER 179
  204. EPILOGUE
  205. THE RELENTLESS PLAYLIST
  206. Acknowledgments
  207. Also by Jonathan Maberry
  208. ABOUT THE AUTHOR
  209. Newsletter Sign-up

The rest of the staff were busy working, but they knew better than to pester the boss and two department heads. There were glances thrown that way, though, and even some unapologetic eavesdropping.

“The problem is,” said Doc, “that we know too much and not enough.”

Her masses of blond hair had spilled out of the bun and hung unevenly around her face, making her look like she’d just come in from riding a horse on a windy heath.

Bug snorted. He was bleary-eyed and unshaven. “Welcome to Rogue Team International, where that is on everyone’s page-a-day calendar for any day ending in a Y.”

“You’re not wrong,” said Church. His only concession to the long hours since Ledger had gone off the radar was that he’d taken his suit jacket off and tugged the knot of his tie loose. He still looked immaculate.

They had cups of coffee and a plate of cookies. Church was nibbling on his fourth vanilla wafer, and no one else seemed interested in cutting into his supply. Doc had a bunch of animal crackers laid out like a parade and was biting off bits of each animal but not eating any whole cookies. Bug sat there, slowly unscrewing double-filled Oreos and eating the cream. Only when he finished the fillings did he begin eating the cookies.

“Ron Coleman and Isaac are studying the cybernetic implants on the patients we brought from Croatia. Right now, there seem to be several kinds of implants. Some have neuro chips, and there’s research suggesting that the chips are designed to interface with add-on gear like a targeting helmet, exoskeleton, or even drones. And there are implants that Coleman is certain will trigger the release of different kinds of chemicals. Some of these chemicals are natural to the body, so the implants regulate those. Dopamine, for example. Or they can sync with a med pack prefilled with drugs. Modifications of modafinil and armodafinil, for sure. They act as selective and atypical dopamine reuptake inhibitors; and then there’s adrafinil, which serves as a prodrug for modafinil. And a prodrug is a compound or medication that, once administered and metabolized into a pharmacologically active drug, controls and improves how the drug is absorbed, distributed, metabolized, and excreted. And we also found experiments with other eugeroics—the norepinephrine–dopamine reuptake inhibitor solriamfetol, and pitolisant, which acts as a histamine receptor antagonist and inverse agonist.”

“Interesting,” said Church.

“And there are other compounds referenced that we haven’t found details on yet. One in particular is R-33. There are notes saying that it’s promising, that tests are showing it to be stable for field use, though of limited duration. And a list of side effects, including possible heart trauma. But we have a ton of stuff to go through, and there’s the encrypted stuff, so maybe it’ll be in there.”